Compare Abbott Laboratories (ABT) vs Colgate-Palmolive Company (CL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Colgate-Palmolive Company — how do they compare? Abbott Laboratories trades at $95.59 (market cap $166.94B), while Colgate-Palmolive Company trades at $93.17 (market cap $76.04B). The key difference: Abbott Laboratories is far larger — about 2.2× Colgate-Palmolive Company's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | CL | |
|---|---|---|
Market Cap | $166.94B | $76.04B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $99.14 |
52-Week Low | $82.57 | $74.98 |
Enterprise Value | $193.69B | $82.68B |
Dividend Yield | 2.63% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Colgate-Palmolive (CL) trades at $95.03, down 0.11% on the day, with a bullish technical outlook supported by moving averages and recent earnings beats. The company maintains strong profitability with a 60.06% gross margin and 10.04% net margin, though its P/E of 36.2 and P/B of 515.38 reflect premium valuation. Positive sentiment is driven by dividend consistency and strategic growth initiatives, while cash flow trends show stable operational performance.
Outlook remains cautiously optimistic with analyst consensus at Buy 42%, Hold 53%, and a $95.50 price target. Key opportunities include international growth and pricing power, but risks involve North American softness and high valuation multiples. The stock's 17% YTD gain underscores resilience, though inflation and competitive pressures warrant monitoring for sustained outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →
